Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02343406 · ClinicalTrials.gov registry record · Phase 2
Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas
A Phase 2 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 2
- Development phase
- 266
- Enrollment target
NCT02343406 is a Phase 2 study that has completed, run by AbbVie. The registered enrollment target is 266 participants.
The verdict
NCT02343406, a Phase 2 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 266 participants
- Enrollment target
Study Summary
This study was conducted to evaluate the efficacy and safety of depatuxizumab mafodotin (ABT-414) alone or with temozolomide versus temozolomide or lomustine alone in adult participants with recurrent glioblastoma. The study also included a substudy to evaluate safety, tolerability and pharmacokinetics of ABT-414 in a pediatric population.
Interventions
- DRUG Temozolomide
- DRUG Lomustine
- DRUG Depatuxizumab mafodotin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 266 participants |
| Start Date | 2015-02-17 |
| Est. Completion | 2019-06-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02343406
The ClinicalTrials.gov registry entry for NCT02343406 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 266 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Temozolomide is the first listed.
NCT02343406 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02343406 about?
NCT02343406 is a clinical study titled "Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas". This study was conducted to evaluate the efficacy and safety of depatuxizumab mafodotin (ABT-414) alone or with temozolomide versus temozolomide or lomustine alone in adult participants with recurrent glioblastoma. The study also included a substudy to evaluate safety, tolerability and pharmacokinet...
What is the current status of trial NCT02343406?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 266 participants. The study started on 2015-02-17. Estimated completion is 2019-06-24.
What interventions are being tested in trial NCT02343406?
The interventions under investigation include: Temozolomide (DRUG), Lomustine (DRUG), Depatuxizumab mafodotin (DRUG).
Who is sponsoring clinical trial NCT02343406?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.